002004 深市 华邦健康

华邦生命健康股份有限公司                                                          财务决算报告

              华 邦生命健康股份有限公司

                2022 年度财务决算报告

    2022 年我国经济平稳运行，虽然发展质量稳步提升但国内经济增速明显放缓。
医药行业处于行业生态发生深远变化的进程中，市场出现短期波动，带量采购、医保控费的趋势没有改变，人民对于医疗健康的底层需求持续增长，不确定性带来的挑战与确定性的增长机遇始终并存。面对复杂环境，公司管理层保持战略定力，沉着应对。过去一年，公司坚定执行医药、医疗“大健康”发展战略，加强新品研发和布局，继续积极管理采购和供应链运营，力争完成 2022 年的经营计划。

    一、2022 年度公司财务报表的审计情况

    （一）公司 2022 年财务报表已经四川华信会计师事务所（特殊普通合伙）审
计，出具了标准无保留意见的审计报告。审计意见为：华邦健康财务报表在所有重
大方面按照企业会计准则的规定编制，公允反映了公司 2022 年 12 月 31 日合并及
母公司的财务状况以及 2022 年度合并及母公司的经营成果和现金流量。

    （二）主要财务数据和指标

    2022 年，公司共计实现营业收入 1,323,236.56 万元，比去年同期增加
80,124.01 万元，同比增长 6.45%；实现营业利润 164,499.97 万元，比去年同期增加 31,135.82 万元，同比增长 23.35%；实现归属于上市公司股东的净利润43,328.28万元，比去年同期减少 23,452.67 万元，同比减幅 35.12%；实现归属于上市公司股东的扣除非经常性损益的净利润40,864.65 万元，比去年同期减少19,922.15 万元，同比减幅 32.77%。

            项目                    2022 年              2021 年          本年比上年增减

营业收入（元）                      13,232,365,567.97      12,431,125,507.27              6.45%

归属于上市公司股东的净利润（元）        433,282,763.85        667,809,439.39              -35.12%

归属于上市公司股东的扣除非经常

性损益的净利润（元）                  408,646,541.75        607,868,012.76              -32.77%

经营活动产生的现金流量净额（元）      2,407,855,343.96      1,269,621,985.57              89.65%

基本每股收益（元/股）                          0.2188              0.3373              -35.13%

稀释每股收益（元/股）                          0.2188              0.3373              -35.13%

加权平均净资产收益率                          4.25%              6.89%              -2.64%


华邦生命健康股份有限公司                                                          财务决算报告

            项目                  2022 年末            2021 年末      本年末比上年末增减

总资产（元）                        30,024,403,300.33      30,039,670,020.31              -0.05%

归属于上市公司股东的净资产（元）    10,191,961,981.05      10,107,152,334.22              0.84%

    二、报告期内公司财务状况、经营成果与现金流量表情况

    （一）财务状况

        项  目                2022 年末                2021 年末          本年比上年增减

 流动资产                        11,554,220,664.68            12,314,051,227.26            -6.17%

 非流动资产                      18,470,182,635.65            17,725,618,793.05            4.20%

 资产总额                        30,024,403,300.33            30,039,670,020.31            -0.05%

 流动负债                        11,111,634,443.77            11,389,234,481.07            -2.44%

 非流动负债                      2,361,978,721.35            2,831,443,147.43          -16.58%

 负债总额                        13,473,613,165.12            14,220,677,628.50            -5.25%

 归属于母公司股东权益            10,191,961,981.05            10,107,152,334.22            0.84%

    主要项目说明：报告期有息负债较上年减少 92,471.92 万元，减幅 10.37%，
具体有息负债情况列示如下：

        项  目                2022 年末              2021 年末          本年比上年增减

 短期借款                        4,576,444,709.86          5,093,468,410.02              -10.15%

 1 年内到期的长期借款            1,678,036,370.22          1,191,547,436.12              40.83%

 其他流动负债                                0            414,405,479.46            -100.00%

 长期借款                        1,741,838,409.95          2,221,617,320.69              -21.60%

 小计                            7,996,319,490.03          8,921,038,646.29              -10.37%

    （二）经营情况

            项  目                  2022 年              2021 年          本年比上年增减

 营业收入                          13,232,365,567.97      12,431,125,507.27              6.45%

 营业成本                            7,874,067,779.57        7,682,257,193.40              2.50%

 销售费用                            1,502,447,565.91        1,615,605,723.88              -7.00%

 管理费用                            1,461,751,628.20        1,199,181,691.27            21.90%

 研发费用                            385,238,749.06          329,471,245.14            16.93%

 财务费用                            207,489,990.31          438,927,988.93            -52.73%

 投资收益                            441,485,183.53          300,008,971.02            47.16%

 信用减值损失                        -23,278,958.26          -25,213,465.70              -7.67%

 资产减值损失                        -560,355,962.85        -138,334,573.98            305.07%


华邦生命健康股份有限公司                                                          财务决算报告

 营业利润                            1,644,999,702.05        1,333,641,491.49            23.35%

 利润总额                            1,622,695,522.35        1,281,246,271.45            26.65%

 净利润                              1,126,736,284.38          920,204,556.34            22.44%

 归属于上市公司股东的净利润          433,282,763.85          667,809,439.39            -35.12%

  主要项目变动说明：

    1、报告期营业收入情况

      项  目                2022 年                    2021 年                同比增减

 营业收入合计                  13,232,365,567.97          12,431,125,507.27                6.45%

 分行业

 医药行业                      3,030,175,292.52          3,003,439,934.04                0.89%

 农化新材料行业                8,949,769,741.37          8,190,675,912.88                9.27%

 旅游服务业                      438,785